Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France

por Druais, Sylvain, Doutriaux, Agathe, Cognet, Magali, Godet, Annabelle, Lançon, Christophe, Levy, Pierre, Samalin, Ludovic, Guillon, Pascal
Publicado 2016

Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Databa...

por Li, Gang, Keenan, Alexander, Daskiran, Mehmet, Mathews, Maju, Nuamah, Isaac, Orman, Camille, Joshi, Kruti, Singh, Arun, Godet, Annabelle, Pungor, Katalin, Gopal, Srihari
Publicado 2021

Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium

por Cai, Rui, Decuypere, Flore, Chevalier, Pierre, Desseilles, Martin, Lambert, Martin, Fakra, Eric, Wimmer, Antonie, Guillon, Pascal, Pype, Stefan, Godet, Annabelle, Borgmeier, Valeria
Publicado 2022